Is clinician impression of depression symptom severity associated with incremental economic burden in privately insured US patients with treatment resistant depression?
- PMID: 31128505
- DOI: 10.1016/j.jad.2019.04.100
Is clinician impression of depression symptom severity associated with incremental economic burden in privately insured US patients with treatment resistant depression?
Abstract
Background: Among patients with major depressive disorder (MDD), those with treatment-resistant depression (TRD) have a higher economic burden. However, the healthcare resource utilization (HRU) and costs may vary by severity status in TRD patients. This study quantified the incremental economic burden of severity status in TRD patients.
Methods: In a US database of privately insured employees and dependents (07/01/2009-03/31/2015), a claims-based algorithm identified adult TRD patients who were stratified into mild, moderate, and severe cohorts based on the information in the last observed MDD ICD-9-CM code. HRU and costs of moderate and severe cohorts were compared to those of the mild cohort during the 2-year follow-up after the first antidepressant claim.
Results: Among 6411 TRD patients, 455 (7.1%) were identified as mild, 2153 (33.6%) as moderate, and 1455 (22.7%) as severe. Moderate and severe patients compared to mild had 45% and 150% more inpatient admissions, 65% and 164% more inpatient days, 18% and 54% more emergency department visits and 8% and 10% more outpatient visits per-patient-per-year (PPPY), respectively (all-cause; all p < 0.05). Mean all-cause direct total healthcare costs were $12,123, $16,885, and $18,911 PPPY in mild, moderate, and severe patients, respectively. The all-cause total healthcare cost differences adjusted for baseline characteristics amounted to $3455 in moderate and $5150 in severe versus mild patients, respectively (PPPY; all p < 0.05).
Limitations: Not all TRD patients had a severity specifier; the severity specifier was not cross-validated against a depression scale.
Conclusions: Increased severity status is associated with incremental economic burden in TRD patients.
Keywords: Costs; Depression severity classification; Economic burden; Healthcare resource utilization; Major depressive disorder; Treatment-resistant depression.
Copyright © 2019 The Authors. Published by Elsevier B.V. All rights reserved.
Similar articles
-
Direct and Indirect Cost Burden and Change of Employment Status in Treatment-Resistant Depression: A Matched-Cohort Study Using a US Commercial Claims Database.J Clin Psychiatry. 2018 Mar/Apr;79(2):17m11725. doi: 10.4088/JCP.17m11725. J Clin Psychiatry. 2018. PMID: 29474009
-
Burden of treatment-resistant depression in Medicare: A retrospective claims database analysis.PLoS One. 2019 Oct 10;14(10):e0223255. doi: 10.1371/journal.pone.0223255. eCollection 2019. PLoS One. 2019. PMID: 31600244 Free PMC article.
-
Economic Burden of Treatment-Resistant Depression in Privately Insured U.S. Patients with Physical Conditions.J Manag Care Spec Pharm. 2020 Aug;26(8):996-1007. doi: 10.18553/jmcp.2020.20017. Epub 2020 Jun 19. J Manag Care Spec Pharm. 2020. PMID: 32552362 Free PMC article.
-
The burden of treatment-resistant depression: A systematic review of the economic and quality of life literature.J Affect Disord. 2019 Jan 1;242:195-210. doi: 10.1016/j.jad.2018.06.045. Epub 2018 Jun 27. J Affect Disord. 2019. PMID: 30195173
-
Repetitive Transcranial Magnetic Stimulation for Treatment-Resistant Depression: An Economic Analysis.Ont Health Technol Assess Ser. 2016 Mar 1;16(6):1-51. eCollection 2016. Ont Health Technol Assess Ser. 2016. PMID: 27110317 Free PMC article. Review.
Cited by
-
How well do clinical and demographic characteristics predict Patient Health Questionnaire-9 scores among patients with treatment-resistant major depressive disorder in a real-world setting?Brain Behav. 2021 Feb;11(2):e02000. doi: 10.1002/brb3.2000. Epub 2021 Jan 5. Brain Behav. 2021. PMID: 33403828 Free PMC article.
-
The Health-Related Quality of Life, Work Productivity, Healthcare Resource Utilization, and Economic Burden Associated with Levels of Suicidal Ideation Among Patients Self-Reporting Moderately Severe or Severe Major Depressive Disorder in a National Survey.Neuropsychiatr Dis Treat. 2021 Jan 18;17:111-123. doi: 10.2147/NDT.S229530. eCollection 2021. Neuropsychiatr Dis Treat. 2021. PMID: 33500620 Free PMC article.
-
A Phase 2 Randomized Trial of NBI-1065846 (TAK-041) in Patients With Anhedonia Associated With Major Depressive Disorder: Results of the TERPSIS Study.J Clin Psychopharmacol. 2025 Sep-Oct 01;45(5):432-440. doi: 10.1097/JCP.0000000000002046. Epub 2025 Jul 28. J Clin Psychopharmacol. 2025. PMID: 40719142 Free PMC article. Clinical Trial.
-
Esketamine versus placebo on time to remission in major depressive disorder with acute suicidality.BMC Psychiatry. 2023 Aug 11;23(1):587. doi: 10.1186/s12888-023-05017-y. BMC Psychiatry. 2023. PMID: 37568081 Free PMC article. Clinical Trial.
-
Prevalence of Pre-existing Conditions Relevant for Adverse Events and Potential Drug-Drug Interactions Associated with Augmentation Therapies Among Patients with Treatment-Resistant Depression.Adv Ther. 2021 Sep;38(9):4900-4916. doi: 10.1007/s12325-021-01862-z. Epub 2021 Aug 9. Adv Ther. 2021. PMID: 34368919 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources